Читаем Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний полностью

Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

Бастиан Блоэм , Майкл Окун , Рэй Дорси , Тодд Шерер

38. State Cancer Profiles. https://statecancerprofiles.cancer.gov. Accessed March 28, 2019.

39. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323; Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143–151.

40. Parkinson Disease Registry. Utah Department of Health. 2018. www. updr.org. Accessed January 4, 2019; Parkinson’s Disease Registry. Nebraska Department of Health & Human Services. 2015. http:// dhhs.ne.gov/publichealth/Pages/ced_parkinsons_index.aspx. Updated February 7, 2018. Accessed January 4, 2019.

41. Tanner CM. California’s Parkinson’s Disease Registry pilot project– coordination center and Northern California ascertainment. Defense Technical Information Center. March 2014. https://apps.dtic.mil/dtic/tr/ fulltext/u2/a601866.pdf. Accessed June 28, 2019.

42. California Parkinson’s Disease Registry. California Department of Public Health. Chronic Disease Surveillance and Research Branch (CDSRB). www.cdph.ca.gov/Programs/ CCDPHP/DCDIC/CDSRB/Pages/California-Parkinson%27s-Disease-Registry.aspx. Updated October 1, 2018. Accessed October 15, 2018.

43. Parkinson Disease Registry. Utah Department of Health. 2018. www. updr.org. Accessed January 4, 2019; Parkinson’s Disease Registry. Nebraska Department of Health & Human Services. 2015. http:// dhhs.ne.gov/publichealth/Pages/ced_parkinsons_index.aspx. Updated February 7, 2018. Accessed January 4, 2019.

44. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323.

45. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.

46. Singleton AB, Farrer M, Johnson J, et al. a-synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841–841.

47. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595–600.

48. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nature Reviews Genetics. 2006;7(4):306–318; Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nature Genetics. 2009;41:1308; Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron. 2010;66(5):646–661; Singleton AB, Hardy JA, Gasser T. The birth of the modern era of Parkinson’s disease genetics. Journal of Parkinsons Disease. 2017;7(Suppl 1):S87-S93.

49. Understanding targeted therapy. American Society of Clinical Oncology. Cancer.net. January 2019. www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy. Accessed March 28, 2019.

50. Jackson SE, Chester JD. Personalised cancer medicine. International Journal of Cancer. 2015;137(2):262–266.

51. Singleton AB, Hardy JA, Gasser T. The birth of the modern era of Parkinson’s disease genetics. Journal of Parkinsons Disease. 2017;7(Suppl 1):S87-S93.

52. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, Mc Inerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.

53. Study goals. Parkinson’s Progression Markers Initiative. www.ppmi-info. org/about-ppmi/study-goals. Accessed March 28, 2019.

54. Access Data & Specimens. Parkinson’s Progression Markers Initiative. www.ppmi-info.org/access-data-specimens. Accessed February 11, 2019.

55. PPMI Clinical Study. The Michael J. Fox Foundation for Parkinson’s Research. www.michaeljfox.org/ppmi-clinical-study. Accessed October 15, 2018.

56. Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Annals of Neurology. 2008;63(2):184–192.

57. Там же.

58. Haddad D, Nakamura K. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson’s disease. FEBS Letters. 2015;589(24 Pt A):3702–3713.

59. Xu L, Pu J. Alpha-synuclein in Parkinson’s disease: from pathogenetic dysfunction to potential clinical application. Parkinson’s Disease. 2016;2016:1720621.

60. Bendor J, Logan T, Edwards RH. The function of a-synuclein. Neuron. 2013;79(6):10.1016/j.neuron.2013.1009.1004.

Перейти на страницу: